Point72 Hong Kong Ltd Takes Position in Genmab A/S (NASDAQ:GMAB)

Point72 Hong Kong Ltd acquired a new stake in Genmab A/S (NASDAQ:GMAB) in the 4th quarter, Holdings Channel reports. The firm acquired 43,671 shares of the company’s stock, valued at approximately $911,000.

Other hedge funds also recently modified their holdings of the company. EverSource Wealth Advisors LLC increased its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its stake in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares in the last quarter. Barclays PLC increased its stake in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after acquiring an additional 2,285 shares in the last quarter. Cromwell Holdings LLC increased its stake in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Genmab A/S during the 4th quarter valued at $93,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

GMAB opened at $19.65 on Friday. The company has a market capitalization of $12.60 billion, a price-to-earnings ratio of 11.29, a P/E/G ratio of 2.65 and a beta of 1.04. The firm’s fifty day moving average price is $19.75 and its two-hundred day moving average price is $20.79. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.06.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Truist Financial decreased their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Finally, Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.